The defining event of Iridium Communications' second quarter is not the headline revenue print but a pair of strategic transactions that together reset the equity's identity for the next eighteen months. On the final Monday of June the company announced a definitive agreement to be acquired by Rocket Lab Corporation in a cash-plus-stock structure. One trading session later the firm closed the buyout of the remaining stake in Aireon Holdings, the joint venture that operates the only space-based ADS-B air traffic surveillance network. The combined package consolidates Aireon under full ownership while handing the Iridium equity story to the acquirer's share price and to the regulatory clearance timeline. Investors are no longer underwriting the standalone satellite-services franchise as the primary thesis; they are underwriting a probability-weighted path through a mid-2027 closing.
Operating performance for the quarter shows the underlying business still expanding but more slowly than during the post-NEXT ramp. Total revenue rose 4% from the prior-year quarter. The engineering revenue line moved up a modest 3%. Operating income fell by one-third as transaction costs tied to the Rocket Lab agreement and the Aireon deal added a large slice to selling, general and administrative expense. Net income slipped by more than half. The billable subscriber base expanded 6% to roughly 2.6 million worldwide. Commercial IoT subscribers led the way, growing 9% year-over-year. The share count sits near 106 million and the equity trades in the mid-$40s against a fifty-two-week band stretching from the mid-teens to the high fifties, leaving a market capitalization of roughly $5B.
The strongest argument for the equity rests on the arithmetic of the announced Rocket Lab consideration. The deal terms grant each Iridium holder a fixed cash payment plus a variable exchange ratio of 0.40 Rocket Lab shares if Rocket Lab's volume-weighted price sits below $67.50. Even at the lower end of Rocket Lab's recent trading range, the implied per-Iridium-share consideration clears the standalone equity price. The principal counterargument is the all-in nature of the deal, which caps standalone upside and replaces organic multiple expansion with regulatory-event risk. Forward variables worth tracking are the Rocket Lab share-price path, regulatory clearance timing, and the third-quarter operating print, a release that includes the first full period of Aireon consolidation and the first read on combined-entity free cash flow generation.